Results may vary. Actual vial appearance, contents, and dosage may vary and is based on your prescription. View full disclaimer in footer.*
Dual GIP/GLP-1 receptor agonist for advanced metabolic and weight management — no injections.
Select Dose / Supply
$379/ month
Includes provider consult, prescription, and shipping.
Tirzepatide is a dual GIP and GLP-1 receptor agonist — the first of its class. By activating two metabolic pathways simultaneously, it produces stronger appetite suppression and greater metabolic effects than GLP-1 alone. The SURMOUNT-1 trial demonstrated average weight loss of 22.5% body weight at the 15mg dose over 72 weeks — the largest weight loss ever recorded in a pharmaceutical trial at the time of publication. Sublingual delivery makes it accessible to patients who prefer not to inject.
*Prices shown reflect the plan you select above — monthly, or quarterly (billed once per 3-month supply). Your final price depends on the specific product, dose, and plan prescribed after your clinical evaluation.
**The FDA does not review or approve any compounded medications for safety or effectiveness.
Compounded medications are not FDA-approved drugs. They are prepared by licensed compounding pharmacies based on a clinician's prescription for an individual patient. Individual results vary. A medical evaluation is required to determine if this therapy is appropriate for you. Some uses discussed may be considered off-label. The FDA does not review or approve any compounded medications for safety or effectiveness.